We are live on ! Find out more
NVET

Nexvet Biopharma plc Ordinary Shares
NVET

Delisted

NVET was delisted on the 28th of July, 2017.

Back to rankings

13 hedge funds and large institutions have $22.6M invested in Nexvet Biopharma plc Ordinary Shares in 2017 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 3 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

4% more capital invested

Capital invested by funds: $21.6M → $22.6M (+$930K)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

28% less funds holding

Funds holding: 18 → 13 (-5)

67% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 3

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 5

Holders
13
Holders Change
-5
Holders Change %
-27.78%
% of All Funds
0.32%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
–
Increased
1
Reduced
3
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Citigroup
Citigroup
New York
+$1.05K

Top Sellers

Rank Fund Capital Flow
1
FCMI
Foresite Capital Management II
California
-$61.7K
2
CI
Cowen Inc
New York
-$43K
3
Bank of America
Bank of America
North Carolina
-$24.6K
4
UBS Group
UBS Group
Switzerland
-$10K
5
Creative Planning
Creative Planning
Kansas
-$4K
Name Holding Trade Value Shares
Change 		Change in
Stake
FCM
1
Farallon Capital Management
California
$10.3M – – –
BC
2
Broadfin Capital
New York
$4.38M – – –
FCMI
3
Foresite Capital Management II
California
$3.41M -$61.7K -17,561 -2%
Adage Capital Partners
4
Adage Capital Partners
Massachusetts
$3.09M – – –
BC
5
Boxer Capital
California
$602K – – –
LLC
6
Latimer Light Capital
New York
$408K – – –
BCM
7
Bridgeway Capital Management
Texas
$173K – – –
Norges Bank
8
Norges Bank
Norway
$133K -$3.51K -1,000 -3%
Citigroup
9
Citigroup
New York
$21K +$1.05K +300 +6%
Morgan Stanley
10
Morgan Stanley
New York
$12K – – –
Bank of America
11
Bank of America
North Carolina
$9K -$24.6K -7,000 -75%
Deutsche Bank
12
Deutsche Bank
Germany
$2K – – –
CI
13
Cowen Inc
New York
– -$43K -11,542 Closed
UBS Group
14
UBS Group
Switzerland
– -$10K -2,750 Closed
Creative Planning
15
Creative Planning
Kansas
– -$4K -1,000 Closed
TRCT
16
Tower Research Capital (TRC)
New York
– -$3K -800 Closed
Acadian Asset Management
17
Acadian Asset Management
Massachusetts
– -$2K -564 Closed

NVET Hedge Fund Activity: Q1 2017 in Review

13 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Nexvet Biopharma plc Ordinary Shares (NVET) for Q1 2017, worth a combined $22.6M — up 4.3% from $21.6M a quarter earlier.

Sellers outnumbered buyers: 5 funds closed out of NVET and 0 opened new positions — a net loss of 5 holders — while 3 trimmed existing stakes and 1 added.

The largest buyer was Citigroup, adding an estimated $1.05K. The largest seller was Foresite Capital Management II, cutting an estimated $61.7K.

  • 13 institutional investors held Nexvet Biopharma plc Ordinary Shares (NVET) as of Q1 2017, down from 18 in Q4 2016.
  • Funds reported $22.6M of Nexvet Biopharma plc Ordinary Shares stock for Q1 2017, up 4.3% quarter-over-quarter.
  • 0 funds opened new Nexvet Biopharma plc Ordinary Shares positions in Q1 2017 and 5 closed out, a net change of -5 holders.
  • The largest Nexvet Biopharma plc Ordinary Shares buyer in Q1 2017 was Citigroup, an estimated $1.05K added.
  • The largest Nexvet Biopharma plc Ordinary Shares seller in Q1 2017 was Foresite Capital Management II, an estimated $61.7K sold.

Based on aggregated 13F filings for Q1 2017.